NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
New Developments in Managing Limited Stage Small Cell Lung Cancer
1.00 AMA PRA Category 1 Credits
Participants should be able to highlight at least 2 key findings of the studies presented in this activity and discuss the applicability of these findings to clinical practice.
Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
||AMA PRA Category 1 Credits
||Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
||Pri-Med Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty and Editorial Board
Bruce E. Johnson, MD, Program Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; Profession of Medicine, Harvard Medical School
Mary Fitzgerald, MS, RN
Financial Disclosure Statement(s)
Dr Johnson has a spouse/partner who receives consulting fees and patent fees from Genzyme.
Ms Fitzgerald has no financial relationships to disclose.
Dana-Farber Cancer Institute
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.